Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the revenue split between Deep TMS device sales and leases or tracking when a director exercises options inside a 200-page filing can feel overwhelming. BrainsWay insider trading Form 4 transactions are scattered across multiple exhibits, while risk disclosures span both U.S. and Israeli regulations. If you have ever typed “BrainsWay SEC filings explained simply” into a search bar, you already know how scarce clear answers are.
Stock Titan ends that search. Our AI-powered summaries turn the latest BrainsWay quarterly earnings report 10-Q filing into an easy-to-scan brief in seconds. The platform streams BrainsWay Form 4 insider transactions real-time, flags option grants, and links them to market-moving announcements. Whether you are understanding BrainsWay SEC documents with AI for a diligence memo or need quick BrainsWay earnings report filing analysis, key figures—installed system count, recurring treatment revenue, R&D spend—stand out instantly.
Every document type is covered: the BrainsWay annual report 10-K simplified highlights reimbursement risk and FDA-cleared indications; the BrainsWay 8-K material events explained alerts you to fresh clinical data or new approvals; and the BrainsWay proxy statement executive compensation reveals how patient-treatment milestones drive leadership bonuses. Investors use these insights to:
- Compare segment margins across device sales and leasing
- Monitor BrainsWay executive stock transactions Form 4 before major data releases
- Track adoption trends quarter over quarter
With real-time EDGAR updates, comprehensive coverage of all forms, and expert notes beside each section, Stock Titan turns dense disclosures into actionable knowledge.
BrainsWay Ltd. (BWAY) submitted a Form 6-K as a foreign private issuer, incorporating this report into its existing Form S-8 and Form F-3 registration statements filed in 2019, 2024, and 2025.
The report includes an exhibit titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder.” This indicates that the company has begun its first clinical trial using the Deep TMS 360 system in the area of alcohol use disorder.
BrainsWay Ltd. furnished a Form 6-K reporting that it received FDA clearance for its Deep TMS therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15 to 21. The update is provided as an exhibit to the report. The company also notes that this Form 6-K is incorporated by reference into its existing U.S. registration statements on Form S-8 and Form F-3.
BrainsWay Ltd. (BWAY) furnished a Form 6-K for November 2025, providing an Investor Deck as Exhibit 99.1. The report notes that the submission is a foreign private issuer filing under the Securities Exchange Act.
The company states that this Form 6-K is incorporated by reference into its existing registration statements: a Form S-8 filed April 22, 2019 and Forms F-3 filed July 22, 2024 and April 22, 2025. The filing itself contains no financial results or transaction details beyond the inclusion of the investor presentation.
BrainsWay Ltd. furnished a Form 6-K. The filing includes an exhibit announcing a National Institutes of Health grant to a leading U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder.
The report states this Form 6-K is incorporated by reference into the company’s Form S-8 and two Form F-3 registration statements.
Brainsway Ltd. reported the appointment of Kost Forer Gabbay & Kasierer, a certified public accounting firm in Israel and a member of Ernst & Young Global, as the companys independent auditors for 2025 and continuing until the next annual general meeting. The Board of Directors is authorized to set the auditors compensation. The filing records a vote tally of 19,070,493 and includes the signature of Ami Boehm.
Brainsway Ltd. submitted a Form 6-K reporting corporate documents and exhibits, and confirming it files annual reports on Form 20-F. The filing incorporates by reference the companys Registration Statement on Form S-8 (Registration No. 333-230979) and two Form F-3 registration statements (Registration Nos. 333-280934 and 333-286672) with respective filing dates of April 22, 2019, July 22, 2024, and April 22, 2025. An exhibit index lists a press release dated August 21, 2025, an Investment Agreement, a Call Option Agreement, Amended and Restated Articles of Association, and a Second Amended and Restated Investors Rights Agreement. The report is signed by Chief Executive Officer Hadar Levy.
FAQ
What is the current stock price of Brainsway Ltd. (BWAY)?
What is the market cap of Brainsway Ltd. (BWAY)?
